Tirzepatide and PCOS: What We Know So Far
PCOS is commonly associated with insulin resistance and, for many patients, with overweight or obesity. One recent study reported weight-loss outcomes among women with PCOS taking tirzepatide. Here's what that study did and didn't show — and the significant limits on what can be concluded from it.
† Tirzepatide is not approved for the treatment of PCOS. Tirzepatide is contraindicated during pregnancy. This article is for educational purposes only, does not constitute medical advice, and is not a recommendation to use tirzepatide for PCOS or for any purpose. Discuss any treatment decision with your licensed healthcare provider.
Key takeaways
Tirzepatide is not FDA-approved for PCOS. It is approved for chronic weight management in adults meeting specific BMI criteria.
A retrospective cohort of 4,241 UK women with self-reported PCOS reported a mean weight loss of 18.81% at 10 months on tirzepatide.
That study measured weight only. It did not assess insulin resistance, androgen levels, menstrual regularity, ovulation, or fertility.
It was presented as a conference abstract, not peer-reviewed, and was conducted by a commercial digital weight-loss service on its own users.
Tirzepatide is contraindicated in pregnancy. Tell your provider if you are pregnant, may become pregnant, or are planning a pregnancy.
Why weight comes up in discussions of PCOS
Polycystic ovary syndrome is one of the most common endocrine conditions affecting women of reproductive age. Estimates of its prevalence vary across sources and diagnostic criteria, commonly ranging from roughly 5% to 15%.
PCOS is frequently associated with insulin resistance, and many — though not all — people with PCOS also have overweight or obesity. Because of these associations, clinical guidelines for PCOS commonly address weight management as one component of care, alongside other approaches.
None of this means that any specific medication is appropriate for any specific person with PCOS. That determination belongs to a licensed provider who knows your history.
What the recent study actually reported
The study
A retrospective cohort study presented at ObesityWeek 2025 examined 4,241 women in the UK with self-reported PCOS and a baseline BMI of ≥30, or ≥27 with at least one other comorbidity, who were prescribed tirzepatide through a digital weight-loss service between February 2024 and January 2025. Participants had a median age of 34 years and a median baseline BMI of 35.56.
The finding
At 10 months, participants had a mean total body weight loss of 18.81% (95% CI, 17.93%–19.69%) after adjustment for age, baseline body weight, and comorbidities. More than 90% of participants achieved at least 10% total body weight loss. Participants who engaged more with the service's digital platform showed greater weight loss than those who engaged less (21.02% vs 17.23%).
What the study does not show — and this matters
It measured weight, and nothing else. The study did not assess insulin resistance, testosterone or other androgen levels, menstrual regularity, ovulation, fertility, acne, or hair growth. It therefore cannot tell us whether tirzepatide improves PCOS itself, as opposed to producing weight loss in people who happen to have PCOS. Those are different claims, and only the second one is supported.
It has not been peer-reviewed. The findings were presented as a conference abstract. Conference abstracts report preliminary work that has not undergone the scrutiny of journal peer review, and findings sometimes change or fail to replicate before formal publication.
PCOS status was self-reported. Participants reported their own PCOS diagnosis; it was not independently confirmed against diagnostic criteria.
The study was conducted by a commercial weight-loss service on its own customers. The research was reported by a clinical director at Voy, a UK digital weight-loss clinic, using data from people who purchased that company's service. The finding that customers who engaged more with the company's platform lost more weight should be read with that context in mind. This is not a criticism of the researchers, but it is relevant to how much weight the results should carry.
It was observational, not a randomized trial. There was no control group. People who choose to start and continue a paid weight-loss program differ in many ways from those who do not.
What is not established
Being direct about the gap between what is known and what is often claimed:
- Whether tirzepatide improves insulin resistance specifically in PCOS beyond what would be expected from weight loss alone.
- Whether tirzepatide reduces androgen levels in PCOS.
- Whether tirzepatide restores menstrual regularity or ovulation in PCOS.
- Whether tirzepatide affects fertility outcomes in PCOS.
- Whether tirzepatide is better or worse than semaglutide, metformin, or any other treatment for PCOS. No head-to-head trial in a PCOS population has been published.
- Whether any of the above holds over the long term, or after treatment stops.
Anyone presenting these as settled is going beyond the evidence.
Pregnancy: a firm contraindication
Tirzepatide is contraindicated during pregnancy
If you are pregnant, think you may be pregnant, or are planning to become pregnant, tell your healthcare provider before starting tirzepatide or as soon as possible if you are already taking it. The same applies to semaglutide.
Because PCOS affects people of reproductive age, this is not a peripheral detail. Any conversation about medication and pregnancy timing — including if, when, and how to stop a medication — must happen with your licensed provider. Do not plan this on your own, and do not rely on any article, including this one, to make that decision.
What to do with this information
If you have PCOS and are considering treatment options, the useful next step is a conversation with a licensed healthcare provider who can review your diagnosis, your health history, your medications, and your goals — including whether pregnancy is part of them.
Bring this article's limitations with you. A provider can tell you what the current evidence supports for your situation, and what it does not.
Frequently asked questions
Is tirzepatide approved for PCOS?
No. Tirzepatide is FDA-approved for chronic weight management in adults meeting specific BMI criteria. It is not approved for the treatment of PCOS. Any use in PCOS would be off-label and is a decision for a licensed provider.
What does the research show about tirzepatide in women with PCOS?
A retrospective cohort of 4,241 UK women with self-reported PCOS prescribed tirzepatide through a digital weight-loss service reported a mean weight loss of 18.81% at 10 months. It was presented as a conference abstract and has not been peer-reviewed. It measured weight only — not insulin resistance, androgens, menstrual regularity, or fertility — so it cannot establish that tirzepatide improves PCOS itself.
Does tirzepatide improve PCOS symptoms like irregular periods or acne?
This has not been established. No published study has demonstrated that tirzepatide improves menstrual regularity, androgen levels, acne, or hair growth in people with PCOS. Claims to the contrary go beyond the available evidence.
Can I take tirzepatide if I am pregnant or trying to become pregnant?
No. Tirzepatide is contraindicated during pregnancy. If you are pregnant, may become pregnant, or are planning a pregnancy, tell your healthcare provider before starting or while taking tirzepatide. Do not make decisions about pregnancy timing and medication on your own.
Is tirzepatide better than semaglutide for PCOS?
Unknown. No head-to-head trial comparing the two in a PCOS population has been published. Comparisons drawn from general obesity trials do not answer this question.
† This article is for educational purposes only and does not constitute medical advice. Tirzepatide is not FDA-approved for the treatment of polycystic ovary syndrome, and nothing here should be read as a recommendation to use it for that purpose. Tirzepatide is contraindicated during pregnancy. The study referenced (presented at ObesityWeek 2025) is a retrospective, non-randomized, non–peer-reviewed conference abstract conducted by a commercial digital weight-loss service among its own users, with self-reported PCOS status, measuring weight outcomes only. Its findings cannot establish efficacy for PCOS. Always consult a qualified, licensed healthcare provider before starting, stopping, or changing any treatment, and tell your provider if you are pregnant, may become pregnant, or are planning a pregnancy. Compounded tirzepatide available through Ondra Health is not FDA-approved and is not reviewed by the FDA for safety, effectiveness, or manufacturing quality.